Pembrolizumab for the treatment of advanced melanoma
Mengarelli C, Ciapponi A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L
Record ID 32016001137
Spanish
Authors' recommendations:
Evidence of moderate quality shows that pembrolizumab used to treat patients with advanced melanoma (metastatic, recurring or non-resecable) might have benefits in survival. The identified studies, with a short-term follow-up, show a potential improvement in overall survival when compared with treatment with ipilimumab and a potential slight increase in disease-free survival when compared with chemotherapy in patients with ipilimumab-refractory melanoma. Its long-term effect should be confirmed in several ongoing studies.
The clinical practice guidelines and United States health sponsors recommend it as first-line therapy in patients who have not been treated with chemotherapy agents or as second-line therapy in patients with advanced cancer not responding to other treatments such as ipilimumab.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Antineoplastic Agents, Immunological
- Melanoma
- Antibodies, Monoclonal, Humanized
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.